Home » Press Releases

Press Releases

Laboratory Glassware

Press Releases

CF Foundation Provides Up to $8.5M to SpliSense to Support a Clinical Trial for a Potential Treatment for Splicing Mutations

Press Releases

SpliSense Announces FDA Clearance of Investigational New Drug Application for Phase 2 Initiation of SPL84 for the Treatment of Cystic Fibrosis

Press Releases

SpliSense is excited to share its most recent press release, announcing the successful completion a first-in-human, Phase 1 clinical trial of SPL84, the company’s lead anti sense oligonucleotide (ASO) product for the treatment of patients with CF, carrying the unmet 3849-splicing mutation.

Press Releases

Vertex and SpliSense Tackle CF with Novel Inhaled mRNA Approaches

Press Releases

SpliSense Initiates Phase 1/2 Study of SPL84, RNA-Based Therapy, for the Treatment of Cystic Fibrosis

Press Releases

First Clinical Trial Begins for RNA-based Therapy SPL84 for CF ,SpliSense treatment would be first for certain CF splicing mutation

Press Releases

Israeli firm SpliSense moves to clinical trials for cystic fibrosis treatment

Press Releases

SpliSense Presents Preclinical Data for SPL23-ASO, mRNA-Altering Drug Candidate for the Treatment of Cystic Fibrosis, at the European Cystic Fibrosis Conference

SpliSense Presents Preclinical Data for SPL23-ASO, mRNA-Altering Drug Candidate for the Treatment of Cystic Fibrosis, at the European Cystic Fibrosis Conference

Press Releases

Splisense raises $28.5 million in series B to advance cystic fibrosis therapy _ 2021-05-14 _ BioWorld

Press Releases

Splisense raises $28.5 million in series B to advance cystic fibrosis therapy

Splisense raises $28.5 million in series B to advance cystic fibrosis therapy By David Ho (/authors/47-david-ho) May 14, 2021 HONG KONG – Splisense